KYMR - NASDAQ
Kymera Therapeutics, Inc.
$73.21
+0.72%Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
At a Glance
Live SnapshotKymera Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Kymera Therapeutics, Inc. Balance Sheet
KYMR • NASDAQ
| Kymera Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
357M | 120.3M | 110M | 68.4M | 48M | 31M | 76M | 41.3M | |
491.3M | 368.5M | 264.9M | 338.8M | 394.4M | 265.2M | 15.9M | 0.0 | |
848.3M | 488.7M | 374.9M | 407.2M | 442.4M | 296.2M | 92M | 41.3M | |
0.0 | 947K | 18.8M | 2.5M | 135K | 1.4M | 0.0 | 148K | |
0.0 | 947K | 15M | 0.0 | 0.0 | 577K | 0.0 | 0.0 | |
0.0 | 0.0 | 3.8M | 2.5M | 135K | 856K | 0.0 | 148K | |
0.0 | 0.0 | 0.0 | 0.0 | 8.7M | 4.7M | 888K | 382K | |
22.9M | 20.6M | 11.7M | 9.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
871.2M | 510.3M | 405.3M | 419.4M | 451.3M | 302.3M | 92.8M | 41.8M | |
NON-CURRENT ASSETS | ||||||||
85.5M | 97.9M | 101.1M | 22.2M | 21.3M | 20.7M | 22.1M | 2.2M | |
777M | 362.2M | 61.4M | 152.3M | 125.2M | 162.5M | 0.0 | 199K | |
9.1M | 7.7M | 7.9M | 9.1M | 8.1M | 1.6M | 1.8M | 0.0 | |
871.6M | 467.8M | 170.4M | 183.7M | 154.6M | 184.8M | 23.9M | 2.4M | |
1.7B | 978M | 575.8M | 603.1M | 605.9M | 487.2M | 116.7M | 44.2M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
4M | 6M | 7.1M | 4.3M | 4M | 4.4M | 3.3M | 2.1M | |
4M | 6M | 7.1M | 4.3M | 4M | 4.4M | 3.3M | 2.1M | |
18.3M | 0.0 | 11.2M | 27.5M | 23M | 10.3M | 4.6M | 1M | |
13.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 13.1M | 6.3M | 3.9M | 3.6M | 3.3M | 3.4M | 302K | |
22.9M | 13.6M | 37.9M | 35.3M | 61.7M | 92.6M | 23.3M | 2.3M | |
24.2M | 35.1M | 23.2M | 303K | 228K | 106K | 0.0 | 1.3M | |
83.2M | 67.8M | 85.7M | 71.3M | 92.5M | 110.6M | 34.6M | 4.7M | |
NON-CURRENT LIABILITIES | ||||||||
11.4M | 0.0 | 16.8M | 28M | 39.3M | 77.8M | 29.6M | 0.0 | |
0.0 | 0.0 | 0.0 | 248K | 66K | 100K | 109.1M | 73.6M | |
79.9M | 74.6M | 95.1M | 41.6M | 53.7M | 92.7M | 156.5M | 74M | |
68.5M | 87.8M | 84.7M | 17.3M | 18M | 18M | 21.2M | 695K | |
163.1M | 142.4M | 180.8M | 113M | 146.3M | 203.3M | 191.1M | 78.7M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 73.4M | |
8K | 7K | 6K | 6K | 5K | 4K | 0.0 | 0.0 | |
2.6B | 1.6B | 926.3M | 878.9M | 689.3M | 412.8M | 2M | 774K | |
-1.1B | -754.6M | -530.8M | -383.8M | -229M | -128.8M | -76.5M | -35.2M | |
1.8M | -1.5M | -552K | -4.9M | -660K | -128K | 6K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -73.4M | |
1.6B | 835.6M | 395M | 490.2M | 459.6M | 283.9M | -74.4M | -34.4M | |
1.6B | 835.6M | 395M | 490.2M | 459.6M | 283.9M | -74.4M | -34.4M | |
SUMMARY | ||||||||
1.7B | 978M | 575.8M | 603.1M | 605.9M | 487.2M | 116.7M | 44.2M | |
1.3B | 730.6M | 326.3M | 491.1M | 519.6M | 427.7M | 15.9M | 199K | |
82.3M | 87.8M | 84.7M | 17.3M | 18M | 18M | 21.2M | 695K | |
-274.8M | -32.5M | -25.3M | -51.1M | -30M | -13M | -54.8M | -40.6M | |
71,949,027 | 71,949,027 | 71,949,027 | 71,949,027 | 71,949,027 | 71,949,027 | 71,949,027 | 71,949,027 |
SEC Filings
KYMR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 10, 2025 | December 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 |
Related Guides
Continue your KYMR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.